title: The prevalence and interaction of human immunodeficiency virus and hepatitis B virus infections in Israeli hemophiliacs.
abstract: The prevalence, clinical manifestations and serological markers of hepatitis B virus (HBV) and human immunodeficiency (HIV) infections were studied in 117 Israeli hemophiliacs. Positive serological markers for HBV infection (HB surface antigen, antibody to HB surface antigen or antibody to HB core antigen) were more common in patients treated with non heat-treated F-VIII concentrates (NHTC) than with cryoprecipitate (48/49 vs. 23/29, P less than 0.05), and in patients treated with greater than 10,000 factor units/year (90% vs. 62%, P less than 0.05). Of the 117 patients, 55% were HIV negative, 29% had asymptomatic HIV seropositivity and 16% had symptomatic HIV infection (lymphadenopathy syndrome, AIDS-related complex or AIDS). HIVB seropositivity was more common in patients treated with NHTC than in those treated with cryoprecipitate (83% vs. 11%, P less than 0.001), and in patients treated with greater than 100,000 compared to less than 10,000 F-VIII units/year (70% vs. 15%, P less than 0.001). Hypergammaglobulinemia correlated with HIV seropositivity, alanine aminotransferase levels and type and amount of concentrate therapy. Of 50 HIV-seropositive patients, 40 (98%) had serological markers of HBV infection compared with only 40 of 52 HIV-negative patients (77%) (P less than 0.01). Symptomatic HIV infection was more common in patients with a positive history of jaundice, 7 of 18 (38%) compared with 12 of 99 (12%) (P less than 0.005). These findings suggest that HBV and HIV infections are less prevalent in cryoprecipitate-treated patients, and that HBV seropositivity is a predictor of HIV seropositivity in hemophiliacs.
authors.affiliation: Hematology Institute, Rambam Medical Center, Haifa, Israel.
authors.forename: B
authors.initials: B
authors.lastname: Brenner
authors.forename: S
authors.initials: S
authors.lastname: Schwartz
authors.forename: E
authors.initials: E
authors.lastname: Ben-Porath
authors.forename: I
authors.initials: I
authors.lastname: Tatarsky
authors.forename: D
authors.initials: D
authors.lastname: Varon
authors.forename: U
authors.initials: U
authors.lastname: Martinowitz
mesh_terms: D005169:Factor VIII / Q000627:therapeutic use; D005340:Fibrinogen / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications / Q000453:epidemiology*; D006679:HIV Seropositivity / Q000150:complications / Q000453:epidemiology*; D006467:Hemophilia A / Q000097:blood / Q000150:complications* / Q000628:therapy; D006508:Hepatitis Antibodies / Q000032:analysis; D006509:Hepatitis B / Q000150:complications / Q000453:epidemiology*; D006515:Hepatitis B virus / Q000276:immunology; D006358:Hot Temperature; D006801:Humans; D007557:Israel / Q000453:epidemiology; D015995:Prevalence
chemical_list: D006508:Hepatitis Antibodies; C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen